CF
OTLK icon

Corebridge Financial’s Outlook Therapeutics OTLK Stock Holding History

Corebridge Financial’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,978
Closed -$9.73K – 1944
2025
Q1 		$9.73K Buy
7,978
+336
+4% +$589 ﹤0.01% 2973
2024
Q4 		$14.4K Sell
7,642
-453
-6% -$1.86K ﹤0.01% 2987
2024
Q3 		$43.2K Buy
8,095
+3,860
+91% +$28.2K ﹤0.01% 2898
2024
Q2 		$31.3K Buy
+4,235
New +$34K ﹤0.01% 2953

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Corebridge Financial's OTLK Position: Q2 2025 in Review

Corebridge Financial sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 7,978 shares — an estimated $9.73K sold.

Corebridge Financial first reported a position in OTLK in Q2 2024 and held it in 4 quarters. The position peaked at $43.2K in Q3 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • Corebridge Financial reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 7,978 Outlook Therapeutics shares in Q2 2025, an estimated $9.73K.
  • Corebridge Financial first reported a position in Outlook Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Outlook Therapeutics position peaked at $43.2K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.